Medomycin

Doxycycline, the active ingredient in Medomycin, is a tetracycline antibiotic presented as an oral dosage form for systemic use. It treats a range of bacterial infections, including respiratory tract infections, acne vulgaris, chlamydial infections, Lyme disease, sexually transmitted infections, and rickettsial diseases, and is prescribed for adults and children as appropriate.

GNH USA supplies Medomycin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and health‑care institutions worldwide, with rigorous quality assurance and regulatory compliance across EU and other markets.

Doxycycline, the tetracycline antibiotic in Medomycin, is used to treat bacterial infections affecting various organ systems.

- Respiratory tract infections: reduces bacterial load and improves symptoms in conditions such as community‑acquired pneumonia and bronchitis. - Acne vulgaris: decreases Propionibacterium acnes colonisation, leading to reduced inflammatory lesions. - Chlamydial infections: eradicates Chlamydia trachomatis, resolving urogenital and ocular disease. - Lyme disease: eliminates Borrelia burgdorferi, preventing early and disseminated manifestations. - Sexually transmitted infections: treats infections like gonorrhoea and syphilis caused by susceptible organisms. - Rickettsial infections: combats Rickettsia species, alleviating fever, rash and systemic involvement.

Doxycycline may cause a variety of adverse reactions, ranging from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may be self‑limiting. - Photosensitivity: increased susceptibility to sunburn. - Esophagitis: irritation or ulceration of the esophagus if not taken with sufficient water. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis or angioedema requiring immediate medical attention. - Stevens‑Johnson syndrome: rare but life‑threatening skin reaction. - Hepatotoxicity: elevated liver enzymes or jaundice. - Intracranial hypertension: headache, visual disturbances, and papilledema. - Hematologic abnormalities: thrombocytopenia or leukopenia.

Before initiating therapy, clinicians should consider several safety factors.

- Pregnancy: Category D – use only when the potential benefit justifies the potential risk to the fetus. - Breastfeeding: caution advised as doxycycline is excreted in milk and may affect the infant. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Sun exposure: advise patients to avoid prolonged UV exposure and use protective clothing. - Drug interactions: review concomitant medications for potential absorption or pharmacodynamic issues. - Store at ambient temperature: keep in the original container, protect from moisture and heat, and store below 25 °C.

Doxycycline interacts with several medicines, necessitating careful management.

Major Interactions (Avoid): - Iron supplements: chelation reduces doxycycline absorption. - Antacids containing aluminum, magnesium, or calcium: impair gastrointestinal uptake. - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk. - Retinoids: combined use raises the risk of intracranial hypertension.

Moderate Interactions (Monitor Closely): - Oral contraceptives: efficacy may be reduced, consider additional non‑hormonal contraception. - Cyclosporine: doxycycline can increase cyclosporine serum concentrations. - Barbiturates and carbamazepine: may accelerate doxycycline metabolism, lowering its effectiveness.